SFJ Pharmaceuticals, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sfj-pharma.com
Clinical Trials
10
Active:4
Completed:4
Trial Phases
3 Phases
Phase 1:6
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Phase 1
6 (60.0%)Phase 2
2 (20.0%)Phase 3
2 (20.0%)Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05162131
- Locations
- π¨π³
Beijing Friendship Hospital, Tongzhou, Beijing, China
Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure
Phase 3
Completed
- Conditions
- HemorrhageUrgent SurgeryInvasive Procedure
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT04286438
- Locations
- πΊπΈ
Intercoastal Medical Group, Sarasota, Florida, United States
πΊπΈUniversity of Tennessee Medical Center, Knoxville, Tennessee, United States
π¨π¦Foothills Medical Centre, Calgary, Alberta, Canada
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo (0.9% Sodium chloride) infusion
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT04122170
- Locations
- πΊπΈ
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
πΊπΈWCCT Global, Inc., Cypress, California, United States
πΊπΈPacific Research Network, San Diego, California, United States
Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo - Sodium ChlorideDrug: PB2452 Infusion
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03928353
- Locations
- πΊπΈ
PPD, Austin, Texas, United States
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PB2452 InfusionDrug: Placebo - Sodium Chloride
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03492385
- Locations
- πΊπΈ
PPD, Austin, Texas, United States
News
No news found